Esopredict™, Previse’s Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett’s Esophagus Prognostic Test. BALTIMORE, Oct. 12, 2023 /PRNewswire/ — Previse, maker of Esopredict, a clinically available test that analyzes…